This study will compare the pharmacokinetics (PK) effect of two different formulations of Gecacitinib Hydrochloride Tablets in healthy Adult participants
Eligibility
Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* 18≤ age ≤ 45, male or female;
* Body weight: ≥50 kg for male, ≥45 kg for female; body mass index (BMI): 19.0-26.0 kg/m\^2 (inclusive);
* Informed consent will be signed before the trial, and the content, process and possible adverse reactions of the study will be fully understood;
* The volunteers should be able to communicate well with the researchers and understand and comply with the requirements of the study.
Exclusion Criteria:
* Participants who were enrolled in a clinical trial or used a study drug within 3 months before administration of the study drug.
* Participants may not be able to complete the study for other reasons or have other reasons for not participating in the study as judged by the investigator.
Primary outcome measure(s)
Maximum Plasma Concentration (Cmax) Of Gecacitinib and its main metabolite ZG0244 — up to 48 hours
Gecacitinib and its main metabolite ZG0244 AUC(0-t) — up to 48 hours
Gecacitinib and its main metabolite ZG0244 AUC(0-inf) — up to 48 hours
Trial sites (1)
Facility
City
Region
Status
The Third Hospital of Changsha
Changsha
Hunan
More Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.